Ciltacabtagene autoleucel, an investigational BCMA-directed CAR-T therapy, sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.
Recent Content
- Preclinical evaluation of TIGIT as a target to enhance efficacy and mitigate T cell exhaustion in multiple myeloma following BCMA-CAR-T therapy
- Dynamics of clonal hematopoiesis and cellular responses to stress-induced toxicity in autologous stem cell transplantation
- Prognostic value of serological and PET/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T
- Author Correction: Microbiota-reprogrammed phosphatidylcholine inactivates cytotoxic CD8 T cells through UFMylation via exosomal SerpinB9 in multiple myeloma
- Pancreatic cancer treatment atebimetinib set for Phase 3 trial
- Toward functional cure in relapsed/refractory multiple myeloma: long-term outcomes from CARTITUDE-1 study cement the role of CAR-T cells
- 1st trial participant receives Alpha DaRT radiation therapy for glioblastoma
- (no title)
- New targeted cancer therapy IDE034 heading to Phase 1 clinical trial
- (no title)